13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE 13D Filed 2026-04-27 Event 2026-04-15 Intent: STRATEGIC SEC 0000905148-26-001871 →

venBio Global Strategic Fund V, L.P. ACHIEVE LIFE SCIENCES, INC. ACHV

Stake: 9.99% Shares: 10,737,317 CUSIP: 004468500 Class: Common Stock, par value $0.001 per share
AI Analyst Brief conf: medium
venBio, a biotech-focused VC/growth fund, filed a 13D on ACHV with 10.7M shares (~significant minority stake) amid 2 other activist filings on the same issuer in the last 90 days, suggesting a contested situation around this small-cap clinical-stage nicotine cessation company; high short interest (DTC 6.79) and no disclosed purpose in the extract leaves intent ambiguous but the 13D form and activi

Item 4 — Purpose of Transaction

The response to Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities reported herein for investment purposes. Subject to a number of factors, including market conditions and their general investment and trading policies, the Reporting Persons may, in the ordinary course of their business, dispose of the shares of Common Stock that they beneficially own. These dispositions may occur in open market transactions, privately negotiated transactions, or through other methods. Additionally, Fund V may distribute the shares of Common Stock that it directly holds to its limited partners. Dr. Royston, who is a member of General Partner V, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Dr. Royston, may engage in discussions from time to time with the Board, the Issuer's management, or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing shares of Common Stock or other securities of the Issuer (collectively, the "Securities"); (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy, or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional Securities through open market transactions, privately negotiated transactions, or other methods.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-03-31
DTC 6.79
7,117,982 shares short · +1.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $374K
Point72 Asset Mgmt

Other 13D/G Filings on ACHIEVE LIFE SCIENCES, INC.

FiledFormFilerStakeShares
2026-04-24 SCHEDULE 13D TPG GP A, LLC 12.60% 13,755,160 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →